MuSK Myasthenia Gravis
Immunology·MeSH: Myasthenia Gravis
Prevalence
20.0 / 100K
Incidence
1.7 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| MuSK-CAART | Cabaletta Bio, Inc. (CABA) |
Frequently asked questions
How many drugs are in development for MuSK Myasthenia Gravis?
BioSniper tracks 1 drug in development for MuSK Myasthenia Gravis across 1 company.
How many clinical trials target MuSK Myasthenia Gravis?
There are 1 clinical trial targeting MuSK Myasthenia Gravis tracked by BioSniper.
What is the prevalence of MuSK Myasthenia Gravis?
The estimated prevalence of MuSK Myasthenia Gravis is approximately 20.0 per 100,000 population.
Deep-dive into MuSK Myasthenia Gravis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis